Evidence from Animal Studies on Fetal Organ Effects
Lurbinectedin, an alkylating agent used in cancer treatment, crosses the placenta and causes embryo-fetal toxicity in animal models. In rats dosed during organogenesis (gestation days 6-15) at exposures below human levels, it led to embryo-fetal lethality, reduced fetal weight, and structural abnormalities including retarded skeletal ossification, malformations of limbs (e.g., adactyly, brachydactyly), tail defects, and craniofacial changes like microphthalmia and anophthalmia. These indicate disrupted growth in skeletal, limb, ocular, and tail structures.[1][2]
In rabbits dosed during organogenesis (gestation days 7-19), post-implantation loss occurred at all doses, with increased early resorptions and decreased live fetuses at exposures approximating human levels. Fetal effects included reduced body weight/length, skeletal variations (e.g., incomplete ossification of sternebrae, ribs, vertebrae), and visceral anomalies like small lungs and liver.[1][2]
Human Data and Pregnancy Category
No adequate human studies exist, but lurbinectedin is pregnancy category D (positive evidence of human fetal risk from animal data). It may cause fetal harm if administered during pregnancy; animal findings suggest potential for organ growth retardation and malformations. Women of reproductive potential must use effective contraception during treatment and for 6 months after.[1][2]
Mechanism Behind Organ Growth Impacts
As an ectopic transcription inhibitor, lurbinectedin traps DNA-topoisomerase I complexes, leading to DNA damage and cell death. Rapidly dividing fetal cells during organogenesis are highly vulnerable, explaining selective impacts on ossifying bones, developing limbs, eyes, and viscera. Reduced fetal weight signals general growth impairment.[1][3]
Clinical Recommendations and Risks
Avoid use in pregnancy; if needed, verify non-pregnancy status before starting. Patients should report pregnancy immediately for counseling. No reversibility data on these effects post-exposure. Sperm donors must abstain from intercourse or use condoms for 4 months post-dose.[1][2]
Alternatives During Pregnancy
No approved chemotherapy alternatives guarantee fetal safety, but non-alkylating agents like certain antimetabolites may have different profiles (consult oncology guidelines). Delaying treatment or supportive care is often preferred.[4]
[1]: Lurbinectedin ( Zepzelca) Prescribing Information, Jazz Pharmaceuticals, 2024
[2]: Drugs.com - Lurbinectedin Use During Pregnancy
[3]: FDA Pharmacology Review for Lurbinectedin, 2020
[4]: NCCN Guidelines: Cancer in Pregnancy, Version 1.2024